Research reference · Separate-vial stack

PT-141 (10 mg) + Melanotan II (10 mg) Stack Dosage Protocol

Written by PeptideDosages Editorial Team Published Updated

PT-141 is dosed at 750 mcg–1.75 mg daily via subcutaneous injection in educational protocols. A 10 mg reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

On this page
  1. Quick reference
  2. Dosage charts and reconstitution
  3. Supplies needed
  4. Vial and research context
  5. Protocol Overview
  6. Dosing Protocols
  7. Storage Instructions
  8. Important Notes
  9. How These Peptides Work
  10. Potential Benefits & Side Effects
  11. Lifestyle Factors
  12. Injection Technique
  13. Recommended Source
  14. Important Note
  15. References
  16. Related research, protocols, and guides

PT-141 + Melanotan II Quick Reference (10 mg + 10 mg Stack)

PT-141

Vial contents
10 mg
Final volume
3 mL
Concentration
3.33 mg/mL
One U-100 unit
33.33 mcg in 0.01 mL
PT-141 10 mg Vial

Melanotan II

Vial contents
10 mg
Final volume
3 mL
Concentration
3.33 mg/mL
One U-100 unit
33.33 mcg in 0.01 mL
Melanotan II 10 mg Vial

Related research: For distinct compound, component, or formulation evidence and safety context, read Melanotan II Peptide: Benefits, Uses, Side Effects, Dosage, and Research and PT-141 Peptide: Benefits, Uses, Side Effects, Dosage, and Research. These links are comparisons only; the compounds and formulations should not be treated as interchangeable.

PT-141 Dosage Chart

Dosing & Reconstitution Guide

Educational guide for reconstitution and dosing of both peptides

Combined Component Schedule (each 10 mg vial prepared separately with 3 mL)

Component Period / Phase Amount per Administration U-100 Units (mL)
PT-141 Initial / Titration 500–750 mcg 15–22 units (0.15–0.22 mL)
PT-141 Standard 1,000–1,500 mcg 30–45 units (0.30–0.45 mL)
PT-141 Full / FDA-approved product amount 1,750 mcg (1.75 mg) 52 units (0.52 mL)
Melanotan II Week 1 250 mcg 7.5 units (0.075 mL)*
Melanotan II Week 2 500 mcg 15 units (0.15 mL)
Melanotan II Weeks 3–4 750 mcg 22 units (0.22 mL)
Melanotan II Weeks 5+ loading 1,000 mcg 30 units (0.30 mL)
Melanotan II Maintenance 500–1,000 mcg 15–30 units (0.15–0.30 mL)

PT-141 frequency: On demand, at least 45 minutes before activity, no more than once in 24 hours or eight times per month[1].

Melanotan II frequency: Once daily during the loading rows; two to three times weekly for the maintenance row.

Reconstitution Steps (prepare each vial separately)

  1. Confirm the correct PT-141 or Melanotan II vial and clean its stopper.
  2. Draw 3.0 mL bacteriostatic water and add it slowly down the wall of that vial.
  3. Gently swirl or roll until fully dissolved; do not shake.
  4. Label the vial with peptide name, concentration, and preparation date; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week stack schedule. The two peptide vials remain separate; the administration supplies are shared.

  • PT-141 Vials (10 mg each):
    • 8 weeks: 2 vials
    • 12 weeks: 3 vials
    • 16 weeks: 4 vials
  • Melanotan II Vials (10 mg each):
    • 8 weeks: 6 vials
    • 12 weeks: 9 vials
    • 16 weeks: 12 vials
  • Shared U-100 Insulin Syringes:
    • 8 weeks: 64 syringes
    • 12 weeks: 96 syringes
    • 16 weeks: 128 syringes
  • Shared Bacteriostatic Water (10 mL bottles):
    • 8 weeks: 24 mL, 3 bottles
    • 12 weeks: 36 mL, 4 bottles
    • 16 weeks: 48 mL, 5 bottles
  • Shared Alcohol Swabs:
    • 8 weeks: 128 swabs, 2 boxes
    • 12 weeks: 192 swabs, 2 boxes
    • 16 weeks: 256 swabs, 3 boxes

Safe disposal: Place used needles and syringes in a puncture-resistant sharps container.

PT-141 10 mg VialView Supplier
Melanotan II 10 mg VialView Supplier
Insulin Syringes
Bacteriostatic WaterView Supplier
Alcohol PadsView Supplier

PT-141 & Melanotan II (10 mg Vials) Dosage Protocol

  • Reconstitute each: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • PT-141 dose: 750–1750 mcg on-demand (≥45 min before activity); max 1 dose per 24 h.
  • Melanotan II dose: 250–1000 mcg once daily with gradual titration.
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F) and use within ~1 week.

PT-141 (bremelanotide) and Melanotan II are cyclic melanocortin receptor agonists with distinct but related applications. PT-141 is FDA-approved for hypoactive sexual desire disorder and is used on-demand[1][2], while Melanotan II has been studied for its effects on skin pigmentation and sexual function with daily dosing protocols[5][6]. This educational guide covers reconstitution, dosing, and administration for both peptides.

Protocol Overview

Summary of both peptide regimens.

  • PT-141: On-demand subcutaneous use for sexual function; typical dose 1.75 mg (1750 mcg) administered ≥45 min before activity[1].
  • Melanotan II: Daily subcutaneous injections during loading phase (4–8 weeks), then 2–3× weekly maintenance for pigmentation and related effects[5].
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for both peptides.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

Dosing Protocols

Key differences between the two peptides.

  • PT-141: Start at 500–750 mcg; titrate to 1750 mcg as tolerated. On-demand use only; max 8 doses/month[2].
  • Melanotan II: Start at 250 mcg daily; increase by 250 mcg every 5–7 days to target 1000 mcg. Transition to maintenance after desired effect[6].
  • Timing: PT-141 at least 45 min before activity; Melanotan II at any consistent time daily.
  • Sites: Rotate injection sites (abdomen, thighs) for both.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; PT-141 shows short-term room-temperature stability (~3 weeks) if needed.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 1 week for optimal potency.
  • Avoid repeated freeze–thaw cycles; allow vials to reach room temperature before opening to reduce condensation.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document each dose, time, and injection site to maintain consistency.
  • PT-141: Do not exceed 8 doses per month or 1 dose per 24 hours[1].
  • Melanotan II: UV exposure (sun or controlled tanning) during use may enhance pigmentation effects; appropriate sun protection is advised[6].

How These Peptides Work

PT-141 and Melanotan II are both synthetic cyclic peptide analogues that act on melanocortin receptors, particularly MC3R and MC4R in the central nervous system[2][5]. PT-141 (bremelanotide) is a metabolite of Melanotan II and was developed specifically for its effects on sexual function without significant pigmentation activity. It is FDA-approved for hypoactive sexual desire disorder in premenopausal women[1][3]. Melanotan II retains both melanogenic and sexual-function properties, stimulating melanin production in skin cells (melanocytes) while also activating central pathways involved in sexual arousal[5][6].

Potential Benefits & Side Effects

Observations from clinical and research literature.

PT-141

  • Shown to increase sexual desire and reduce distress associated with low libido in clinical trials[2][3].
  • Common side effects include nausea (especially with first doses), flushing, headache, and injection-site reactions[4].
  • May cause transient increases in blood pressure; use with caution in those with cardiovascular conditions[1].

Melanotan II

  • Studied for inducing skin pigmentation (tanning) without UV exposure and for effects on erectile function[5][6].
  • Common side effects include nausea, facial flushing, fatigue, and appetite suppression, particularly during initial dosing[6].
  • May cause darkening of existing moles or nevi; monitoring is advised.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Maintain adequate hydration, especially given potential nausea with initial doses.
  • For Melanotan II users seeking pigmentation: controlled, gradual UV exposure may enhance results; always use appropriate sun protection to minimize skin damage risk.
  • Prioritize sleep and stress management; both influence hormonal balance and overall response.
  • Monitor for any new or changing skin lesions and consult a healthcare provider if noted.

Injection Technique

General subcutaneous guidance from clinical best-practice resources[8][9].

  • Clean the vial stopper with an alcohol swab; allow to dry completely.
  • Clean the injection site (abdomen or thigh) with an alcohol swab for at least 30 seconds; allow to dry[8].
  • Pinch a fold of skin; insert the needle at 45–90° depending on subcutaneous tissue depth[9][10].
  • Aspiration is not required for subcutaneous injections; inject slowly and steadily[8].
  • Release the skin fold, withdraw the needle, and apply gentle pressure if needed.
  • Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy or irritation[9].

Recommended Source

We recommend Pure Lab Peptides for high-purity PT-141 and Melanotan II (10 mg vials).

Why Pure Lab Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.

PT-141 Product ID: 10mg vial  |  Melanotan II Product ID: 10mg vial

Shop PT-141
Shop Melanotan II

Important Note

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References

  • 1

    FDA
    — Bremelanotide (Vyleesi) prescribing information: dosing, safety, and use limitations
    View Source
  • 2

    NCBI Bookshelf (LiverTox)
    — Bremelanotide: mechanism, clinical use, and hepatic safety profile
    View Source
  • 3

    PMC
    — Bremelanotide for treatment of female hypoactive sexual desire disorder: clinical trial review
    View Source
  • 4

    Mayo Clinic
    — Bremelanotide (subcutaneous route): side effects, dosage, and precautions
    View Source
  • 5

    PubMed
    — Evaluation of Melanotan-II: pilot phase-I clinical study on safety and efficacy
    View Source
  • 6

    RxList
    — Melanotan-II: uses, side effects, dosing, and precautions overview
    View Source
  • 8

    NCBI Bookshelf (WHO)
    — Best practices for injections and related procedures: asepsis and technique
    View Source
  • 9

    Healthline
    — Subcutaneous injection: technique, sites, and step-by-step guidance
    View Source
  • 10

    CDC
    — Vaccine administration: subcutaneous injection angle and site selection
    View Source
  • 12

    Pure Lab Peptides
    — PT-141 (10 mg) product page: quality and batch documentation
    View Source
  • 13

    Pure Lab Peptides
    — Melanotan II (10 mg) product page: quality and batch documentation
    View Source

Additional Research and Background

These sources provide related context and are not presented as support for a specific statement above.

  • 1

    PMC
    — Subcutaneous drug injection: pharmacologic considerations and clinical review
    View Source

Related research, protocols, and guides

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.

Research overview

Related protocols and comparisons

Practical guides